Dyslipidaemia, hypercoagulability and the metabolic syndrome.
| Title | Dyslipidaemia, hypercoagulability and the metabolic syndrome. |
| Publication Type | Journal Article |
| Year of Publication | 2006 |
| Authors | Kakafika, A. I., Liberopoulos E. N., Karagiannis A., Athyros V. G., & Mikhailidis D. P. |
| Journal | Curr Vasc Pharmacol |
| Volume | 4 |
| Issue | 3 |
| Pagination | 175-83 |
| Date Published | 2006 Jul |
| ISSN | 1570-1611 |
| Keywords | Adipose Tissue, Adiposity, Animals, Aspirin, Cardiovascular Diseases, Cholesterol, HDL, Clofibric Acid, Dyslipidemias, Factor VII, Fibrinolytic Agents, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Inflammation Mediators, Insulin Resistance, Life Style, Lipoproteins, LDL, Metabolic syndrome, Obesity, Plasminogen Activator Inhibitor 1, Thrombophilia, Triglycerides, von Willebrand Factor |
| Abstract | The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension. This syndrome is associated with increased risk of cardiovascular disease and is a common early abnormality in the development of type 2 diabetes. The pathogenesis of the syndrome has multiple origins. Obesity and sedentary lifestyle coupled with genetic factors interact to produce the syndrome. Here, we consider two components of the metabolic syndrome, dyslipidaemia and hypercoagulability. |
| Alternate Journal | Curr Vasc Pharmacol |
| PubMed ID | 16842135 |
